Abstract:Kai Dong, 1, 2 Shu-Jing Deng, 2 Bin-Yang He, 2 Zi-Yang Guo, 2 Ze-Lin Guan, 2 Xue Leng, 2 Rui-Rui Ma, 2 Dan-Yang Wang, 2 Jian-Feng Xing, 2 Cui-Yu You 1 1 Department of Pharmacy, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, People's Republic of China; 2 School of Pharmacy, Xi'an Jiaotong University, Xi'an, Shaanxi, People's Republic of China Correspondence: Jian-Feng Xing, School of Pharmacy, Xi'an Jiaotong University, 76 Yanta West Road, Xi'an, 710061, Shaanxi, People's Republic of China, Tel +86-29-82655139, Fax +86-29-82655139, Email Cui-Yu You, Department of Pharmacy, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, People's Republic of China, Tel +86-29-85323241, Fax +86-29-85323240, Email Background: As the first-line drug to treat ulcerative colitis (UC), long-term use of glucocorticoids (GCs) produces severe toxic and side effects. Local administration as enema can increase the local GCs concentrations and reduce systemic exposure to high oral doses by directly delivering GCs to the inflammation site in the distal colorectum. However, UC patients are often accompanied by diarrhea, leading to the short colonic residence time of GCs and failure to exert their function fully. Purpose: A kind of mucoadhesive nanoparticles (NPs) loading different dexamethasone derivatives (DDs) were developed, which could attach to the positively charged inflammatory colonic mucosa through electrostatic adsorption after administered by enema, thereby improving the local concentration and achieving effective targeted therapy for UC. Methods: Two DDs, dexamethasone hemisuccinate and dexamethasone phosphate, were synthesized. In NPs preparation, The core PEI-DDs NPs were built by the electrostatic adsorption of DDs and the cationic polymer polyethyleneimine (PEI). Then, the natural polyanionic polysaccharide sodium alginate (SA) was electronically coated around NPs to construct the final SA-PEI-DDs NPs, followed by the in vitro stability and release tests, in vitro and in vivo colonic mucosal adhesion tests. In the in vivo anti-UC test, the experimental colitis mice were induced by 2,4,6-trinitrobenzenesulfonic acid. The body weight and disease activity index changes were measured, and the myeloperoxidase activity, pro-inflammatory cytokines concentration, and hematoxylin and eosin staining were also investigated to evaluate the therapeutic effect of NPs. Results: The structures of two DDs were demonstrated by 1 H-NMR and MS. Both NPs were negatively charged and achieved high loading efficiency of DDs, while their particle sizes were significantly different. NPs showed good stability and sustained release properties in the simulated colonic environment. Moreover, the negative charge on the of NPs surface made them easier to adhere to the positively charged inflammatory colonic mucosa, thereby enhancing the enrichment and retention of DDS in the colitis site. Furthermore, the NPs exhibited better therapeutic effects than free Dex on the experimental colitis mice induced by TNBS through the enema rectal. Conclusion: These results indicated the mucoadhesive NPs as a kind of novel nano-enema showed great potential to achieve efficient treatment on UC. Keywords: ulcerative colitis, glucocorticoids, mucoadhesive, polyethyleneimine, sodium alginate Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by diffuse mucosal inflammation in the distal colon and rectum. 1,2 UC has a long course of the disease and is prone to recurrence, thus seriously affecting patients' life quality. Glucocorticoids (GCs) are the first-line drugs for patients with moderate to severe UC, which can inhibit the production of inflammatory mediators (such as leukotrienes, prostaglandins, etc.), cytokines [such as interleukins, tumor necrosis factor-α (TNF-α), interferon, etc.] and nitric oxide (NO) by regulating gene transcription. 3–6 However, since GCs affect substance metabolism, long-term oral administration of GCs induces severe systemic side effects, including endocrine disorders, cardiovascular diseases, osteoporosis, ophthalmic diseases, nervous system diseases, gastrointestinal adverse reactions, etc. 7,8 Therefore, targeted delivery of GCs to the colitis site improves the local anti-inflammatory effect of GCs and reduces their systemic side effects. Enema administration is commonly used to treat intestinal diseases. 9–11 Research reports that two-thirds of UC patients with diffuse inflammation will occur in the distal colon, which needs local enema administration. Therefore, enema adm -Abstract Truncated-

Synthesis of an Enzyme—dependent Prodrug and Evaluation of Its Potential for Colon Targeting

Delivery of Glucocorticoid Conjugate in Rat Gastrointestinal Tract and Its Treatment for Ulcerative Colitis.

[Pharmacokinetics of Site-Specific Delivery of Dexamethasone-Dextran Prodrug in Rat Gastrointestinal Tract].

[Characteristics of Drug-Release in Vitro of Different Dextran-Dexamethasone Conjugates].

Synthesis and Characterization of Azo-Containing Dextran Hydrogels as Carriers for Colonic Drug Targeting

Design of colon-targeted drug delivery of dexamethasone: Formulation and in vitro characterization of solid dispersions

Preparation of budesonide–dextran conjugates using glutarate spacer as a colon-targeted drug delivery system: in vitro/in vivo evaluation in induced ulcerative colitis

Assessment of the drug loading, in vitro and in vivo release behavior of novel pH-sensitive hydrogel

Prodrugs for colon-restricted delivery: Design, synthesis, and in vivo evaluation of colony stimulating factor 1 receptor (CSF1R) inhibitors

Synthesis and Antitumor Activity of Stearate-G-dextran Micelles for Intracellular Doxorubicin Delivery.

Esterification of Salicylic acid with Succinylated Dextran Using ZrOCl2.8H2O over MCM-41: A Novel Strategy to Design Polysaccharide-Based Macromolecular Prodrugs

A Lipophilic Prodrug of Danshensu: Preparation, Characterization, and in Vitro and in Vivo Evaluation

Chitosan-modified lipid nanodrug delivery system for the targeted and responsive treatment of ulcerative colitis

Eudragit S100 coated microsponges for Colon targeting of prednisolone

An efficient enzyme-triggered controlled release system for colon-targeted oral delivery to combat dextran sodium sulfate (DSS)-induced colitis in mice

In Vitro and in Vivo Evaluation of a Novel Capsule for Colon-Specific Drug Delivery.

Mucoadhesive Nanoparticles Enhance the Therapeutic Effect of Dexamethasone on Experimental Ulcerative Colitis by the Local Administration as an Enema

Bifunctional Succinylated ε-Polylysine-Coated Mesoporous Silica Nanoparticles for pH-Responsive and Intracellular Drug Delivery Targeting the Colon

One‐Pot Synthesis of pH‐Responsive Eudragit‐Mesoporous Silica Nanocomposites Enable Colonic Delivery of Glucocorticoids for the Treatment of Inflammatory Bowel Disease

SDH, a novel diarylheptane compound, alleviates dextran sulfate sodium (DSS)-induced colitis by reducing Th1/Th2/Th17 induction and regulating the gut microbiota in mice

Oral absorption enhancement of dipeptide L-Glu-L-Trp-OH by lipid and glycosyl conjugation